National Brain Tumor Society announces launch of the Defeat GBM Research Collaborative
BOSTON—With an ambitious goal and perhaps even more ambitious timetable, the National Brain Tumor Society announced March 26 the formation of the Defeat GBM Research Collaborative, a strategic research initiative with a goal to double the five-year survival rate of patients with glioblastoma multiforme (GBM)—the most common and deadliest form of brain cancer—in just five years.
To achieve this goal, those running the Defeat GBM Research Collaborative plan to connect leading brain tumor researchers from top cancer institutions across the globe, in a "tightly focused and goal-driven effort," the National Brain Tumor Society says. "Through research collaboration, synergistic projects will be combined and driven by investigator teams with proven track records of results to create significant improvement in patient survival. "
The primary goal will be to share data among all projects and investigator teams within Defeat GBM to better inform the overall effort and to advance potential therapies down the drug discovery pipeline.
"Defeat GBM draws upon successful science and proven funding models from other disease populations that have yet to be utilized in brain tumor research," said N. Paul TonThat, executive director of the National Brain Tumor Society. "The brain tumor community can no longer spend years and millions of dollars to achieve only incremental progress in this deadly disease."
Participating researchers and investigator teams for key projects within Defeat GBM will initially stem from such institutions as the University of Texas MD Anderson Cancer Center and the Ludwig Institute for Cancer Research. The Initiative will also actively collaborate with the National Foundation for Cancer Research (NFCR) on a parallel bioinformatics and GBM genomics project, which capitalizes on NFCR's longstanding relationship with the Tissue Bank Consortium in Tianjin, China.
The National Brain Tumor Society touts various "additional and unique aspects" of the program, which include simultaneous research efforts in basic discovery science, translational science, preclinical drug development and clinical trial design, all of which is "intended to identify the right biological targets and attack them with the right therapies in the right patients."